Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 77Terminated 23Active not recruiting 22Recruiting 13Withdrawn 10Unknown 8Not yet recruiting 2Enrolling by invitation 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1

Interventions

Radiotherapy 2Lenalidomide 2Carboplatin 2tislelizumab 1irinotecan sucrosofate 1enzalutamide 1Ruthenium-106 1Radiotherapy, Intensity-Modulated 1Paclitaxel 1Melphalan 1Mannitol 1Leukocyte Count 1Folfox protocol 1Dexamethasone 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Enrolling by invitation × Lenalidomide × Clear all
NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

HuniLife Biotechnology, Inc.

Phase 1/2 Enrolling by invitation
21 enrolled
Plasma cell

Multiple Myeloma

NCT06762431 2025-01-07

VTB-CLL002

Vitebsk Regional Clinical Cancer Centre

Phase 1/2 Enrolling by invitation
60 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡